Bioventix PLC
LSE:BVXP

Watchlist Manager
Bioventix PLC Logo
Bioventix PLC
LSE:BVXP
Watchlist
Price: 3 750 GBX 1.08% Market Closed
Market Cap: 195.7m GBX
Have any thoughts about
Bioventix PLC?
Write Note

Bioventix PLC
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bioventix PLC
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Bioventix PLC
LSE:BVXP
Capital Expenditures
-ÂŁ5.3k
CAGR 3-Years
70%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Capital Expenditures
-$169k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Capital Expenditures
-$11m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Capital Expenditures
-$916k
CAGR 3-Years
14%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Capital Expenditures
-ÂŁ5.4m
CAGR 3-Years
-21%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Capital Expenditures
-ÂŁ24.7m
CAGR 3-Years
10%
CAGR 5-Years
3%
CAGR 10-Years
-14%
No Stocks Found

Bioventix PLC
Glance View

Market Cap
195.7m GBX
Industry
Biotechnology

Bioventix Plc engages in the development and supply of antibodies. The company is headquartered in Farnham, Surrey and currently employs 17 full-time employees. The company went IPO on 2014-04-29. The principal activity of the Company is the development and supply of antibodies. The firm specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics, such as in automated immunoassays used in blood testing. The firm offers a portfolio of antibodies to customers for both commercial use and research and development (R&D) purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The firm also supplies antibody products and services to multinational clinical diagnostics companies. The firm sells its products through direct sales and through distributors.

BVXP Intrinsic Value
3 076.09 GBX
Overvaluation 18%
Intrinsic Value
Price

See Also

What is Bioventix PLC's Capital Expenditures?
Capital Expenditures
-5.3k GBP

Based on the financial report for Dec 31, 2023, Bioventix PLC's Capital Expenditures amounts to -5.3k GBP.

What is Bioventix PLC's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
49%

Over the last year, the Capital Expenditures growth was 72%. The average annual Capital Expenditures growth rates for Bioventix PLC have been 70% over the past three years , 49% over the past five years .

Back to Top